Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3748304 | 0.89 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL30157405 | 0.85 | P2RX7 (0.92) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL30157766 | 0.81 | CYP3A4 (0.73) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL30157599 | 0.81 | P2RX7 (0.71) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL30158687 | 0.79 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL30158127 | 0.79 | P2RX7 (0.64) | P2RX7 | |
| SCHEMBL30158533 | 0.78 | P2RX7 (0.66) | P2RX7CYP2D6CYP2C19RAB9A | |
| SCHEMBL30157903 | 0.77 | ALDH1A1 (0.73) | P2RX7CYP2D6CYP2C19 | |
| SCHEMBL3746001 | 0.77 | P2RX7 (0.62) | P2RX7CYP2D6PKMCYP2C19 | |
| SCHEMBL2581958 | 0.77 | P2RX7 (1.00) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292295-A1 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-18 | — | — | US | claimed |
| US-20100292295-A1 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-18 | — | — | US | disclosed |
| US-20100292295-A1 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-18 | — | — | US | disclosed |
| WO-2009077559-A2 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292295-A1 | 5-OXO-3-PYRROLIDINECARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | P2RX3, P2RX6, P2RX7 | P2RX7 3/4885CYP2D6 804/4885PKM 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.